Medically reviewed by Jay N. Yepuri, MD Medically reviewed by Jay N. Yepuri, MD A pancreatic elastase test, also known as a ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients ...

Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the ...

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with ...

5). Several serine proteases, including neutrophil elastase, cathepsin G and proteinase-3, are implicated in the destruction of alveolar tissue 18, and are therefore potential targets for treatment.

Krystal Biotech is gearing up for a very important Q4 of 2024, because it is gearing up to report data from two different ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation ...